NASDAQ · XOMA
XOMA Royalty Corp.
$40.17$0.00 (0.0%)
XOMA Royalty Corp.’s quoted price sits in the upper half of its reported 52-week range, 11.17% below the high.
Loading market information…
NASDAQ · BNTC · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Benitec Biopharma Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Benitec Biopharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q2 2025 | Feb 14, 2025 | -$0.36+64.0% vs estimate | $0.00 |
|---|
| Q1 2025 | Nov 14, 2024 | -$0.48+12.73% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $17.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$40.17$0.00 (0.0%)
XOMA Royalty Corp.’s quoted price sits in the upper half of its reported 52-week range, 11.17% below the high.
$6.39-$0.09 (-1.39%)
Solid Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
$2.88-$0.02 (-0.69%)
I-Mab’s quoted price sits in the lower half of its reported 52-week range, 57.58% below the high.
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
$1.58-$0.05 (-3.07%)
Autolus Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
£1.18£0.00 (0.0%)
PureTech Health plc’s quoted price sits in the lower half of its reported 52-week range, 18.11% below the high.
$1.75+$0.03 (+1.74%)
Quantum-Si incorporated’s quoted price sits in the upper half of its reported 52-week range, 20.09% below the high.
$1.03-$0.01 (-0.96%)
Lineage Cell Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
